Newswire (Published: Wednesday, July 3, 2019, Received: Wednesday, July 3, 2019, 6:31:52 PM CDT)

Word Count: 424

2019 JUL 03 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Data detailed on Oncology - Prostate Cancer have been presented. According to news reporting originating from Maryland, United States, by NewsRx correspondents, research stated, “Testosterone promotes the initial development of androgen-dependent prostate cancer. This is the basis for androgen ablation treatment, which attenuates, but does not terminate, the malignancy.”

Our news editors obtained a quote from the research from the Department of Oncology and Diagnostic Sciences, “Instead, it leads to prolactin-dependent malignancy; in which patient death generally occurs within 5 years. This report describes the novel treatment of a patient; which terminated androgen-independent prostate cancer. Patient ‘XY’ was diagnosed with prostate malignancy and metastases. He received hormonal androgen ablation treatment, chemotherapy, and radiation treatment. He developed androgen-independent prostate cancer; with expected death in 2-3 years. He was treated with cabergoline (dopamine agonist) treatment, which decreased the plasma prolactin 88%; by inhibiting the pituitary production of prolactin. The subsequent PET scan (positron emission tomography) revealed the absence of malignancy; and the CTC (circulating tumor cells) decreased from count=5.4 to count=0. The cause of androgen-independent malignancy has been unknown, and an effective chemotherapy did not exist. The activities of normal and malignant prostate cells are regulated primarily by testosterone. When testosterone availability diminishes; prolactin regulation is manifested. This is represented when androgen ablation results in the development of prolactin-dependent malignancy. An effective chemotherapy would be targeted to eliminate the plasma prolactin-manifestation of the androgen-independent malignancy. This report of a novel chemotherapy for androgen-independent malignancy corroborates our understanding of the implications of prolactin in its development and treatment. There are about 165,000 cases/year with 25,000 deaths/year in the U.S.; and 1.0 million cases/year with 260,000 deaths/year worldwide.”

According to the news editors, the research concluded: “Those patients with androgen-independent prostate cancer can now employ this cabergoline treatment to prevent or terminate this deadly type of prostate cancer.”

For more information on this research see: A Novel Patient Case Report to Show the Successful Termination of Untreatable Androgen-independent Prostate Cancer: Treatment with Cabergoline (Dopamine agonist). Mathews Journal of Case Reports, 2019;4(1):.

The news editors report that additional information may be obtained by contacting L.C. Costello, Dept. of Oncology and Diagnostic Sciences, University of Maryland School of Dentistry and The University of Maryland Greenebaum Comprehensive Cancer Center Baltimore, Maryland 21201, United States. Additional authors for this research include R.B. Franklin and G.W Yu.

(Our reports deliver fact-based news of research and discoveries from around the world.)


      Medical Devices
            Medical Treatment Devices
                  Radiosurgery Devices
      Medical Device Manufacturing
            Medical Devices
                  Medical Treatment Devices
                        Radiosurgery Devices


North America
United States


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer